TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.

Autor:	Thielmann, Carl M.1 (AUTHOR) carlmaximilian.thielmann@uk-essen.de, Matull, Johanna1 (AUTHOR), Zaremba, Anne1 (AUTHOR), Murali, Rajmohan2 (AUTHOR), Chorti, Eleftheria1 (AUTHOR), Lodde, Georg1 (AUTHOR), Jansen, Philipp1 (AUTHOR), Herbst, Rudolf3 (AUTHOR), Terheyden, Patrick4 (AUTHOR), Utikal, Jochen5 (AUTHOR), Pföhler, Claudia6 (AUTHOR), Ulrich, Jens7 (AUTHOR), Kreuter, Alexander8 (AUTHOR), Mohr, Peter9 (AUTHOR), Gutzmer, Ralf10,11 (AUTHOR), Meier, Friedegund12 (AUTHOR), Dippel, Edgar13 (AUTHOR), Weichenthal, Michael14 (AUTHOR), Kretz, Julia1 (AUTHOR), Möller, Inga1 (AUTHOR)
Zdroj:	European Journal of Cancer. Jan2022, Vol. 161, p99-107. 9p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect